This document is a publication of a United States Patent and Trademark Office (USPTO) patent application, specifically application number US20260083732A1, filed on September 6, 2023. The application, titled 'Upadacitinib pharmaceutical composition with hydrophobic polymer,' describes a novel formulation for the drug upadacitinib. The core of the invention lies in a pharmaceutical composition that includes upadacitinib or its pharmaceutically acceptable salt, a release-controlling hydrophobic polymer, a pH modifier, and other pharmaceutical excipients.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on pharmaceutical companies. However, it signifies potential future intellectual property protection for a specific drug formulation. Companies involved in the development or manufacturing of upadacitinib or similar JAK inhibitors should be aware of this filing as it may impact their own research, development, and commercialization strategies. No specific actions are required from compliance officers at this stage, but monitoring patent landscapes remains a routine compliance activity.